Skip Navigation
Search Menu

 
Print This Page
Share this page: More
 

Clinical Trials

Johns Hopkins Kimmel Cancer Center Melanoma Researchers

Although significant progress has been made in the treatment of melanoma, many important clinical questions still need to be answered. We continue to explore the frontiers of discovery in the treatment of melanoma thanks in part to the many patients who willingly to participate in new treatment trials. Participation in a new treatment trial can be a rewarding option for the appropriate patient. Clinical trial availability changes frequently. If you are a melanoma patient at Johns Hopkins Kimmel Cancer, please ask your health team about clinical trial participation. If you are not a Johns Hopkins patient but would be interested in participating in a trial, please contact us at 410-955-8804.

Melanoma Clinical Trials Available at Johns Hopkins (Kimmel Cancer Center searchable database.)

Summary of Current Melanoma Trials

Hopkins Melanoma Program: Open and Accruing Clinical Trials

Stage IV (metastatic) or unresectable Stage III

  1. J13101: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors.
    This study tests BMS-986016 (Anti-LAG-3) and BMS-936558 (nivolumab, anti-PD-1) in patients with advanced solid tumors, including melanoma. Anti-LAG-3 and nivolumab are drugs that help to activate the immune system. Patients must:
    • have an unresectable or metastatic solid tumor excluding primary brain cancer
    • provide a baseline tumor biopsy
    • have never received cancer immunotherapy, though prior adjuvant therapy is allowed with at least a six-month interval between that treatment and trial enrollment.
    • be willing to undergo an on-treatment tumor biopsy

 

  1. J14182 - A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC).
    This trial studies how well pembrolizumab (anti-PD-1) works in treating patients with Merkel cell carcinoma (MCC) that cannot be removed by surgery or has spread to other parts of the body. Requirements:
    • Patients 18 years or older with unresectable Stage III or Stage IV Merkel cell carcinoma
    • No prior therapy for metastatic Merkel cell is allowed, though prior adjuvant therapy is permitted
    • Initial results from this trial

 

  1. J14144: Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced/Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma.
    This study tests urelumab and nivolumab (anti-PD-1) in patients with advanced melanoma. Urelumab and nivolumab are drugs that help to activate the immune system. Requirements:
    • Patients 18 years or older with unresectable Stage III or Stage IV melanoma
    • Patients must have had progressive disease during or after treatment with anti-PD-1 with or without CTLA-4

 

  1. J1647: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301).
    Requirements:
    • Patients 18 years or older with unresectable Stage III or Stage IV melanoma
    • Prior anti-PD-1, anti-PD-L1, or IDO1 inhibitor treatment is not permitted
    • Prior ipilimumab therapy is permitted only as adjuvant treatment
    • Patients with ocular melanoma are excluded

 

  1. J15117: Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors.
    This study tests nivolumab and ipilimumab in several dose combinations, in patients with advanced virus-associated tumors including Merkel cell carcinoma. Therapy is administered prior to surgery to remove stage III Merkel cell carcinoma. Requirements:
    • Patients 18 years or older with resectable Stage III Merkel cell carcinoma
    • Prior anti-PD-1 treatment is not permitted

 

  1. J15214 - A Pilot Study of Stereotactic Radiosurgery combined with Nivolumab in Patients with Newly Diagnosed Melanoma Metastases in the Brain and Spine.
    This study is being done to look at the safety of using stereotactic radiosurgery (SRS) and nivolumab (anti-PD-1) together to treat melanoma that has spread to the brain or spine. Both nivolumab and SRS are used separately for the treatment of advanced melanoma. We are testing these therapies together because there is laboratory evidence that suggests that the combination may be more powerful than either treatment by itself. Nivolumab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma that has spread throughout the body. It works by activating your immune system to fight off cancer. Stereotactic radiosurgery uses radiation to treat tumors without needing to cut or use stitches, and is approved by the FDA for the treatment of melanoma in the brain or spine. Requirements:
    • Patients with melanoma that has spread to the brain or spine
    • Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PDL-2 antibody is not permitted
    • Prior whole brain radiation or conventional radiation to the spine at the site of new lesion is not permitted
 

 

NCI CCC